Answers are grounded in this paper and cite their sources.
Gentamicin-associated nephrotoxicity remains a major limitation of aminoglycoside therapy, particularly in critically ill patients with acute kidney injury (AKI). Nevertheless, gentamicin may still represent the only microbiologically active treatment option for infections caused by multidrug-resistant Gram-negative pathogens. This case describes an 85-year-old woman with severe cardiac comorbidity who developed stage III AKI and sepsis secondary to pyelonephritis caused by multidrug-resistant Klebsiella pneumoniae susceptible only to gentamicin. Owing to the high risk of further renal deterioration, treatment was initially started with a markedly conservative regimen of gentamicin 10 mg intravenously once daily under therapeutic drug monitoring (TDM). Twenty-four hours after the first dose, the trough concentration was 0.51 mg/L, whereas the peak concentration measured after the subsequent 10 mg dose was only 0.89 mg/L, indicating profound underexposure. Following consultation in clinical pharmacology, therapy was individualized using a model-informed precision dosing (MIPD) approach with predefined pharmacokinetic/pharmacodynamic goals: peak concentration ( C max) of 10–12 mg/L and trough concentration below 1.0–1.5 mg/L. A regimen of 160 mg intravenously every 72 h was selected and later shortened to every 48 h as renal function improved. During treatment, serum creatinine decreased from 363 µmol/L to 166 µmol/L, inflammatory markers declined, sepsis was controlled, and the patient was discharged without clinical or laboratory evidence of ongoing infection. This case demonstrates that gentamicin can be used effectively and safely in selected critically ill patients with AKI when dosing is guided by TDM and model-informed individualization.
No takes yet. Share an insight, caveat, or question.
Irfan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: